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Abstract
Chemical biology is the scientific discipline that deals with the application of 
chemical techniques and often small molecules produced through synthetic chem-
istry, to the manipulation and study of biological systems. Its working framework 
ranges from simple chemical entities to complex drugs by employing the principles 
of biological origin. This chapter particularly focuses on the principles and working 
models of chemical biology to discover new drug leads. Drug discovery is an extensive 
and multifaceted complex process. Chemical biology uses both natural and synthetic 
compounds with the best therapeutic potential and verifies them by employing the 
best possible chemical toolsets. Screening of compounds is done by the use of pheno-
typic as well as the target-based screening to identify and characterize the potent hits. 
After the identification of target, it is characterized, and validated by extensive test-
ing. The next step is the validation of hits obtained, and lead compounds are tested in 
clinical trials before introducing them for commercial application.
Keywords: chemical biology, drug discovery, target identification, target validation, 
phenotypic screening
1. Introduction to chemical biology and history
Chemical biology flourished as a discipline of science which makes use of several 
aspects of chemistry to understand biology [1]. Chemical biology includes a wide 
range of fundamental problems related to the understanding of complex biological 
processes by the development of synthetic frameworks to generate selective and 
active lead compounds [2].
The roots of history of chemical biology lie in the emergence of chemistry and 
biology as separate disciplines. Chemical biology flourished as a separate discipline 
of science because of newer challenges and questions for the study of chemi-
cal methods employed on living bodies. This branch of study is concerned with 
advanced molecular concepts of biology harnessed to the use of chemical entities. 
In spite of the newness of this concept, the history of chemical biology extends 
up to two centuries, considering the foundations of chemistry and biology. Here 
only a brief account of history of chemical biology is discussed. Joseph Priestley 
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discovered nitrous oxide gas in 1772 and incubated the mice with “airs” (the gases 
discovered till that time). He used 10 gases including nitrous oxide on experimental 
mice. His experiments on mice faced a strong mass discontent from Americans 
who showed a sympathetic behavior towards animal rights. Thus, the first chemical 
biologist fell a prey to angry mob due to his experiment on mice [3].
Afterwards, another chemist, Humphry Davy, worked (1778–1829) on the newly 
isolated and unfamiliar gases at that time. Frightened by the previous experiment, 
Humphry completely omitted the use of mice and decided to carry out the research 
on himself. It was not a matter of surprise that one of the gases, carbon monoxide, 
proved fatal for the scientist, but the pleasant effect of nitrous oxide made him 
name this gas, “the laughing gas.” He also investigated the use of this gas in medical 
surgeries. Samuel Taylor also documented this gas as a pleasure-making gas [4], 
but the practical use of this gas in medicine was described in 1844 by an American 
Figure 1. 
History of chemical biology with its eminent events.
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dentist, Horace Wells [5]. In 1998, three scientists, namely, Ferid Murad, Robert 
Furchgott, and Louis Ignarro, won Nobel Prize for the demonstration of significant 
role of nitric acid in cell signaling [6].
Wöhler is a well-known scientist in the history of chemical biology. He attempted 
to lay the basis of chemical biology by carrying out his research on vitalism. He 
prepared urea from inorganic chemicals and rejected the famous “vital force theory” 
in 1828 [7]. The next important event in the history of chemical biology “cellular 
imaging” was revolutionized by utilizing the chemical approaches during the nine-
teenth century. John Hershel invented the cyanotype process which was brought into 
practice by Anna Atkins to prepare delicate botanical specimens. This noble lady also 
published her book entitled as Photographs of British Algae: Cyanotype Impressions [8].
Ehrlich (1854–1915) is thought to be the pioneer of the earliest forms of chemo-
therapy and drug therapy. He carried out numerous experiments on aniline based 
dyes and proposed the idea of “magic bullets.” He said that these magic bullets 
are capable of targeting specific pathogens. He discovered a chemical compound 
Salvarsan, a drug used against syphilis. This compound is also called as Ehrlich’s 
606th compound, it was named so because of the successful compound he discovered 
after 605 failed target compounds. The discovery of this compound paved a way for 
the discovery of new chemical entities or the new “magic bullets” [6, 9] (Figure 1).
Chemical biology flourished as an eminent scientific discipline due to significant 
contributions of Koehler (pioneer of various chemical screening approaches), 
Saghatelian (discovery and characterization of lipids and peptides), Wang (use of 
chemoproteomics in determination of electrophilically lipidated cellular proteins), 
and Patti and Northen (metabolomics analysis) [1].
2. Chemical biology tools
2.1 Chemical probes
Chemical probes are the small molecules which bind to the specific targeted sites 
and initiate their cellular activities. These archetypal tools act as highly valued reagents 
for molecular- and genetic-level biological research. Chemical probes are helpful in the 
accurate investigation of biological pathways and their associated targets [10].
2.2 Antisense and RNAi technologies
Many tools have been involved in target validation since the 1980s. Target iden-
tification and validation are long procedures. They were mainly based on structure-
activity relationship. The drug discovery system becomes the most important 
approach towards the targeted cells [11]. Traditional antisense and RNA interference 
(RNAi) technologies are the robust tools used in multidimensional phases to discover 
and validate the potential drug targets. This approach elaborates the potentially 
selective cleavage of a targeted messenger RNA. This targeting technique enables the 
researchers to explore the protein-based expression on phenotypes [12].
2.3 Protein degradation strategies
2.3.1 Induced protein degradation
Induced protein degradation is an event-driven approach which depends on drug 
binding and eliminating the target protein after tagging it. This approach is gaining 
attention in recent times because of the selective degradation of the target proteins. 
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Drug discovery based on small molecules focuses on the loss of function of proteins 
due to the already-occupied binding sites ultimately making the proteins unable to 
target. In this approach, there is a need of high drug exposure in vivo to avoid target 
inhibition conditions which may lead to potentially harmful side effects of that 
drug. Proteolysis-targeting chimeras (PROTACS) use the cellular quality control 
setup to degrade the selective proteins as their targets. This protein degradation 
system reduces the quantity of drug to be exposed to the living systems which are to 
be used for halting the protein functions. These proteins may belong to regulatory 
proteins, transcription factors, and scaffolding proteins [13, 14].
2.3.2 Chemoproteomics
Chemoproteomics is employed as a chemical tool for target identification. It can 
be used to investigate the signal transductions. This particular field of study has 
flourished as a key technology to characterize the action mechanism of chemical 
probes and drugs which can act as pharmacological modulators, hence validating 
the cellular targets of several therapeutic drug candidates. Chemoproteomics can 
be further characterized as affinity- and activity-based chemical proteomics [15]. 
In some cases when probe development is a difficult task, multiple kinase inhibitors 
are used for targeting the kinome effectively [16].
3. Drug discovery
Drug discovery is a hectic multistep procedure comprising of highly systematic 
approaches to identify, and characterize different compounds leading towards 
the development of hits and validate them extensively via utilization of chemical 
toolsets to attain the status of a commercial therapeutic drug status. The important 
steps of drug discovery are mentioned in Figure 2.
3.1 Screening
There are two fundamental approaches which can be used for the purpose 
of drug discovery, namely, phenotypic screening and target-based screening. 
Figure 2. 
A diagram representing the summary of key notes regarding drug discovery from natural products.
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The first one looks at the effects of phenotype that the compound induces on cell, 
tissue or whole organism, and the second one evaluates the effects of a compound 
on a purified target protein.
3.1.1 Phenotypic screening
In the early twentieth century, drug development started with the advancements 
in pharmacology and synthetic and therapeutic chemistry. In the 1950s and 1960s, 
enzyme kinetics has provided methods for accurate computation of compound’s 
effectiveness and enzyme competence [17].
Between 1999 and 2008, the US Food and Drug Administration (FDA) approved 
new drug discovery approaches. During this period, 75 small molecules were dis-
covered and analyzed. Out of these, 28 drugs were discovered through phenotypic 
selection, and 17 drugs were identified by target dependent selection [18].
“Alemtuzumab” was the first antibody that was been obtained by using hybridoma 
technology in combination with phenotypic identification. It was previously reported 
against relapse of multiple sclerosis and chronic lymphocytic leukemia (CLL). The 
CD44 antigen (cell surface glycoprotein) antagonist, RG7356, was isolated with the 
help of function F.I.R.S.T™ platform. Therefore, functional assays antibodies were 
used to check effects on cell signaling, proliferation, and programmed cell death [19].
Large combinatorial antibody libraries are the sources of human monoclonal 
antibodies, successfully used in medical and phenotypic screening. For example, 
BI-505 was isolated by using F.I.R.S.T™ platform. Improved versions of antibodies 
were ultimately used in simulation studies of tumor cell death assay and for selec-
tive B-lymphoma cell surface binding. Soon after the isolation of BI-505, its molecu-
lar target was identified as ICAM-1, which were found to be involved in apoptosis of 
B-lymphoma cells. BI-505 has a broad antimyeloma activity [20].
By using phenotypic screening technology, patients can increase their effective 
antibody response like B-cell repertoire. For example, from a healthcare worker, 
anti-respiratory syncytial virus (RSV) antibody, D25, was isolated. On the virus 
coat, D25 neutralizes RSV, and perfusion structure of the F protein was expressed 
which was not identified by target-based screening [21]. The use of phenotypic 
screening in various experiments is outlined in Table 1.
Disease Cells Assay type Time 
duration
References
Breast cancer MCF7-RFP
MDA-RFP
Cytochemical and 
immunohistochemical staining 
analyses
8–10 days [22]
Idiopathic 
pulmonary 
fibrosis
Alveolar 
epithelial 
type II cells
Immunofluorescence staining for 
in vitro, Western blot, FACs, ELISA, 
in vitro biochemical kinase assay, 
migration assay
13 days [23]
Respiratory 
papillomatosis
Lung tumor 
cells
Cell viability assay 48 hours [24]
Cystic fibrosis Bronchial 
epithelial cell
Western blots 18–24 days [25]
Huntington’s 
disease
PC12 Protease release assay 48 hours [26]
Familial 
dysautonomia
Neural crest 
precursors
RT-PCR assay 48 hours [27]
Table 1. 
Phenotypic screening used in some experiments.
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3.1.2 Target-based screening
Target-based screening of natural compounds and synthetic chemicals is being 
considered as a significant innovation for anticancer drug development [28]. In 
2007, Lysine demethylase 5B (KDM5B) and Histone demethylase were recognized, 
which are liable for the removal of H3K4me2/3 activation marker. Thus, for cancer 
therapy, KDM5B is regarded as a promising drug target, but the elevated levels of 
KDM5B were found in many human cancers [29].
The respiratory chain of Streptococcus agalactiae consists of two enzymes; 
type 2-NADH dehydrogenase (NDH-2) and cytochrome bd oxygen reductase. 
S.  agalactiae is considered as the primary cause of sepsis and meningitis in neonates 
as well as considerable cause of pneumonia and urinary tract infection [30]. The 
difference between phenotypic and target-based screening is shown in Figure 3.
Some of the target-based screening methods are mentioned as follows.
3.1.2.1 Mass spectrometry-based method
Mass spectrometry is known to be a highly efficient technique for the identification 
and structural characterization of natural products derived from herbal medicine [31].
Target-based method relies on mass spectrometry to search for active com-
pounds, and this technology can be used for identification, structural characteriza-
tion, quantitative elemental analysis, tracking of key intermediate compounds in 
a chemical reaction, analysis of pharmaceuticals and metabolites, and elucidation 
of unknown structures in drug development. All these achievements can be finally 
used in various applications like pharmaceutics (drug developments, pharma-
cokinetics, metabolic pathways), clinical screening, etc. On the basis of MS data 
information of compounds, the UniFi™ platform has been built for more detailed 
analysis of structures [32].
3.1.2.2 Liquid chromatography-mass spectrometry (LC-MS)
LC-MS is an analytical technique for separating different complex mixtures 
into their components using liquid chromatography. These assays check the cor-
rect synthesis, purity, various physical and chemical properties like their volatility 
and active functionalities present in the newly synthesized chemical entities [33]. 
During drug discovery, LC-MS hyphenated technique is used for seperation and 
structural characterization of compounds [34].
Figure 3. 
The action potential of phenotypic as well as target-based screening of compounds to validate the hits and leads 
from natural and synthetic compounds.
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3.1.2.3 Gas chromatography-mass spectrometry (GC-MS)
GC-MS is another hyphenated technique for the identification and structure elu-
cidation of unknown compounds derived from natural products [35]. For example, 
by using GC-MS technique, comprising a gas chromatograph (GC) coupled to a mass 
spectrometer (MS), complex components of natural oils mixtures may be separated, 
identified, and quantified, e.g., oils extracted from Apiaceae family (Anethum 
graveolens, Carum carvi, Cuminum cyminum, Coriandrum sativum, Pimpinella anisum, 
Daucus carota, Apium graveolens, Foeniculum vulgare, and Ammi visnaga). As a result 
of this separation technique, petroselinic acid was the major fatty acid from all other 
palmitic, palmitoleic, stearic, petroselinic, linoleic, linolinic, and arachidic acids [36].
3.1.2.4 Ultra-performance liquid chromatography-mass spectrometry (UPLC-MS)
Currently, UPLC-MS is one of the most adaptable hyphenated techniques. 
Proteomics and metabolomics have proved to be useful concepts for understand-
ing the causes of different diseases. This technology aims to seperate and identify 
proteins and metabolites for cellular signaling pathways and to discover biomarkers 
for screening and diagnosis as well as determining response to a specific treatment 
[37]. For example, vancomycin (VCM) is clinically used for the treatment of human 
intracranial infections. The treatment concentration of vanomycin greatly varies 
among the patients. UPLC-MS technique was  developed and used for the analysis of 
VCM in human cerebrospinal fluid [38].
3.1.2.5 Nuclear magnetic resonance spectroscopy (NMR)
Among the common techniques of metabolomics, NMR has evolved the most. 
Unlike mass spectroscopy, NMR is also used for quantitative analysis, but it does not 
require extra steps for sample preparation [39]. It is commonly used to analyze the 3D 
structures of biomacromolecules and their interactions. It has been proved a valuable 
tool for the reliable identification of small molecules that bind to proteins and for 
hit-to-lead optimization. Mainly, NMR spectroscopy is suitable for the analysis of bulk 
metabolites [40]. NMR has been used for analyzing the structure of protein, nucleic 
acid, and small molecule [41]. NMR has been proven to be a useful tool in target-based 
drug discovery in the step of hit identification and lead optimization [42]. For example, 
NMR spectroscopy is used to understand the structure of G-quadruplexes, which are 
noncanonical, four standard nucleic acids with consecutive sequences of guanines [43].
3.1.2.6 Thermal shift or calorimetry-based method
Isothermal titration calorimetry (ITC) is the only technique which is currently 
available for the direct determination of enthalpy, ΔH, of a ligand binding to a 
protein [44]. Thermodynamic evaluation might be useful to provide information 
about specificity, agonist versus antagonist effects of ligands, and other important 
properties [45]. Fragment-based drug discovery (FBDD) is an approach of par-
ticular interest and relevance here. Fragments are molecules smaller than typical 
drugs, and they generally bind with lower affinity than conventional drug screen-
ing hits [46]. Measuring the contributions of enthalpy and entropy to the free 
energy of binding provides information that can be useful in fragment elaboration 
and subsequent medicinal chemistry work [47]. ITC is a uniquely powerful tool 
for characterization of the thermodynamics of test compounds binding to target 
proteins. Interaction between the compound and protein leads to release or uptake 
of small amounts of heat, while the mixture is held at a close approximation to 
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constant temperature [48]. Thermal shift screening methods has allowed to identify 
compounds that interact with Trypanosoma brucei choline kinase (TBCK) and 
inhibit TBCK, a validated drug target against African sleeping sickness [49].
3.1.2.7 Affinity-based methods
The methods regarding affinity-based immobilized proteins have vital role in 
understanding the connections between small molecules and their biological targets 
[50]. Affinity-based technologies are divided into two groups: (1) direct detection 
of noncovalent macromolecule-ligand complex and (2) indirect detection of nonco-
valent macromolecule-ligand complex. The negative aspect of this approach is that 
it recognizes chemical entities basically based on their binding affinities for a target 
irrespective of whether or not the biological function of the target is affected. In the 
late 1980s, matrix-assisted laser desorption ionization (MALDI) and electrospray 
ionization (ESI) techniques were used to analyze proteins and nucleic acids. Both 
phenotypic screening and target-based screening are comparable to each other in 
terms of benefits and drawbacks. This fact has been illustrated in Figure 4.
4. Target identification and characterization
Target identification and elucidation of its action mechanism have played vital 
roles in probing small molecules and drug discovery. Target identification has been 
based on biological and technologically advanced cell-based assays [51].
4.1 Disease association and target validation
Identification of the molecules and their underlying pathophysiological mecha-
nisms contribute towards the discovery of targets that can be modulated therapeuti-
cally [52]. Each drug target is linked to a disease using integrated genome-wide data 
from a broad range of data sources. The target validation reveals the evidence that 
associates a target with a disease [53].
Figure 4. 
Comparison between the advantages and disadvantages of target-based and phenotypic screening based upon 
the different features such as molecular target of disease, its mechanism of action, confirmation methods, SAR 
optimization methods, and hypothesis limitation.
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4.2 Bioactive small molecules
Bioactive small molecules are preferred as lead structures for the target valida-
tion. These small molecules isolated from phenotypic screen play a crucial role in 
chemical biology [54, 55]. Many genomic, proteomic, and bioinformatic technolo-
gies have been developed for validation of the drugs.
4.3 Protein interactions
To identify the selective potent drugs, the first step is to find the protein 
interference. In signal transductions, protein-protein interactions are involved 
in the complex cellular networks that govern the different processes [56]. The 
deregulated transcription factors are involved in playing significant roles in 
human pathological abnormalities, but the complicated nature of protein-protein 
networks has made the transcription-targeted therapeutics impractical. Recent 
technological advancements are the ray of hope regarding the modulation of 
protein interaction networks [57].
4.4 Cell-based models and target validation
Exosomes are highly adequate for drug carriers as a cell-based model. Due to 
the association of multiple proteins with cellular membranes, the exosomes are 
well-known in cell to cell communication, and they are the novel approach for the 
delivery of potent drugs. Exosome-based drug technique is applied for a variety of 
disorders such as cancer and various neurodegenerative disorders [58].
5. Target validation
Drug target discovery and validation demand complicated and expensive frame-
works which may pose heavy financial load on pharmaceutical industry. Target valida-
tion is referred to as the direct involvement of a certain molecular target in pathological 
conformity; hence, its reversal or inflection may have a therapeutic effect [12].
5.1 Approaches to target validation
The following approaches are used in target validation during the discovery and 
development of drug.
5.1.1 Antibodies
Firstly access the antibody fitness towards a specific target. Then, standardized 
procedures are obligatory to ensure the quality of the sample in test procedures; 
hence, utilizing only a single approach will not work in all situations [59]. Mass 
spectrometry is used to identify the validation of the antibody. This type of tech-
nique confirms the validity for antibodies or their fragments against the targets. 
The antibody is able to bind to its natural antigen in cell lysates among thousands of 
other proteins, DNA, RNA, and other cellular components [60].
5.1.2 Cellular thermal shift assay (CETSA)
CETSA is used to assess the capability of a ligand to bind with its targets (cells or 
tissue samples). The basis of this method lies on the ligand-induced thermodynamic 
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stabilization of target proteins. The compound-treated cell lysates and intact cells 
were heated to different temperatures, and in the soluble fractions, the target 
protein was separated from destabilized protein and detected by Western blotting. 
SPROX is a method of target validation based on identification of ligand-induced 
stabilization of target proteins. It evaluates the levels of methionine oxidation of 
target proteins [61].
5.1.3 Drug affinity responsive target stability (DARTS)
DARTS has been used for the identification of the targeted proteins. It is based 
on ligand binding interaction with proteins forming a complex which changes the 
structural stability of target protein. There alteration is measured by SDS page/
liquid chromatography. DARTS is also involved in the analysis of the low affinity 
interactions [61].
6. Hit generation
Hit identification is considered as the significant bottleneck for lead generation 
success and for new medicines. An example for random hit identification is physical 
and biochemical testing [62]. The journey of a compound from the hit status to lead 
status follows a series of steps which have been briefly illustrated in Figure 5. The 
figure describes a note of possible techniques which could be utilized for the selec-
tion of lead compounds and proceeding them through lead optimization preclinical 
and clinical phase trials.
Figure 5. 
A diagram elaborating the significant steps of lead optimization proceeding to clinical phase of natural 
compounds.
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7. Development of lead drug
Pharmaceutical companies are facing constant economic pressure to bring efficacy 
in drug discovery and development process. Lists of compounds obtained after hit 
optimization are further subjected to refining process in order to find out the lead 
compounds that can be analyzed for production at commercial scale. During this “hit-
to-lead” refining process, many compounds are dropped out due to inadequate absorp-
tion, distribution, metabolism, excretion, and toxicity/ADMET characteristics [63].
Refining of hit compounds to lead compound is done through the process of 
secondary screening. Almost 50% of all drug candidates thin out during optimiza-
tion and preclinical and clinical trials [64].
There are many approaches available for the discovery and development of drug 
which might follow different pathways to optimize the compounds into bioavailable 
drugs. All these pathways must have a common origin; they all begin with a lead 
compound. It is necessary to go through the phylogeny study of all the compounds 
because there are some properties like solubility, target affinity, toxicity, ease of 
synthesis, and bioavailability, all of which are highly dependent on the initial lead 
selection and the method of identification [65].
7.1 Techniques of lead selection
A rational approach is used to select lead drug candidate after optimization 
of hit compounds. There are many methods which can be used for screening of 
compounds. Selection of techniques depends upon the source of hit compounds and 
types of their solvents as well. The following techniques are useful in selection.
7.1.1 QSAR model development
Quantitative structure-activity relationship model is used to compare chemical 
structures by using database of prior selected active compounds. Different software 
like ChemBioOffice Ultra 1.11 is used to generate two-dimensional and three-
dimensional structures. The results of QSAR can be validated by using statistical 
approaches like correlation coefficient and regression coefficient [66].
7.1.2 Visualization of SAR activity
It is called as Bayesian approach. It provides with proficient understanding of 
shape features, hydrophobic nature, and electrostatic properties of the compounds. 
All of these features lie under the structure–activity relationship of selected com-
pounds from hits. Structure data analysis of SAR is obtained in 3D form. Other 
results are obtained in diverse type of interrelated biochemical data, i.e., average of 
activities and region explored analysis. The results obtained from average activity 
show a common part in active compounds, and region explored data exhibit the 
areas of fully explored compounds [67].
7.1.3 Fragment-based drug discovery
It is a powerful method which is used to find out the proportion of ligands with 
high affinity to target proteins. The compounds which are found to have low ligand 
binding ability are eliminated, and the compounds with high ligand ability move 
forward to the precision of compounds. FBDD consists of the techniques such as 
NMR, SAR, X-ray crystallography, and surface plasmon resonance (SPR).
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7.1.3.1 X-ray crystallography
It can ascertain the binding sites and modes of ligand binding to protein [68].
7.1.3.2 Surface plasmon resonance (SPR)
Surface plasmon resonance is known as a nonlabel technology that can iden-
tify, screen, and quantify intermolecular interactions in actual time. It is applied 
to quantify binding affinities. SPR-dependent biosensors work by detecting the 
ligands and immobilized target molecular interactions and supply appropriate 
information on kinetics of biomolecular interactions. The output information 
can be utilized to provide comprehensive functional data on binding actions 
such as specificity, kinetics, concentration, and affinity [69]. Scientific litera-
ture study revealed Biacore tools as mainly used SPR technology at commercial 
levels [70].
7.2 Preclinical trials
In the last 2 years, different methodologies based on high-throughput screening 
and their combinations with chemistry have been developed in order to manufac-
ture versatile compounds by limiting the resources. Among these methodologies, 
several other in vitro and in silico supplementary approaches have also come 
forward for the identification and potential evaluation of these compounds as lead 
candidate validation. Those compounds which are selected as “hits” during this 
screening procedure are further analyzed and subjected to in vivo toxicity and effi-
cacy profiling. During preclinical stage of drug development, simple formulation 
approaches are favored. Combinatorial chemistry and high-throughput approaches 
have been appraised in several publications [71].
PLOTs are preclinical lead optimization technologies that should be rapid 
enough to edge with high-throughput discovery screenings without causing 
further delay and should be predictive and cost-effective. PLOT platform usu-
ally comprised of in vitro systems, small and acquiescent to mechanization, and 
that is why it is easy to achieve the mandatory throughput with minimum use of 
compound use [72].
7.2.1 Tools of preclinical drug development
Selection of methodology and tools for selection of preclinical drug candidates is 
a rigorous process. Sequential approach of preclinical to clinical is practiced to sort 
out the long list of target selected compounds. This streamline strategy provides with 
deeper understanding of action of the drug prior to its progress to the next steps [73].
7.2.2  Pharmacokinetics and pharmacodynamics (PK/PD) during preclinical drug 
evaluation
Pharmacodynamics involves the study of effect of drug in dose- and time-
dependent manner. Pharmacokinetics is the study of absorption, metaboliza-
tion, distribution, and excretion of a drug over time. PK/PD is a program at 
early phase of lead drug development which acts as a bridge between drug 
discovery and preclinical drug development. This stage set aims for further 
development activities, and information obtained at this stage act as a key to 
subsequent steps.
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It is necessary because of the following reasons:
a. It provides potency-based intrinsic activity of the compound rather than dose.
b. It characterizes the compounds on the basis of dose concentration and effect 
relationship.
c. It allows the investigation of tolerance phenomenon of compounds on the basis 
of physiological parameters [74].
7.3 Lead optimization
Optimization of a drug is a multifaceted process. It usually involves various 
types of screening methods which tend to find out the metabolism and pharmaco-
kinetic properties of selected compounds or drugs [75].
7.3.1 ADME
This is the final stage of preclinical trials; after this the optimized drug is 
further processed towards the clinical trial. Absorption, distribution, metabo-
lism, and excretion screening is performed at this stage. The primary goal of 
ADME is to develop a competitive drug with adequate safety avoiding PK failure 
in clinical phase.
7.3.2 ADME properties
Ideal properties of a drug in ADME testing involve the good oral bioavailability, 
blood clearance and volume of convenient dosing, and low potential of drug-drug 
interaction. All of these properties are assessed at early stage of drug discovery [76].
7.3.3 DRUGeff
Drug effect is a parameter which determines the concentration of a drug which 
do not cause any harm at the site of action. In other words at this stage, toxicity of 
a drug is tested to find out the minimum safe dosage potency. In vitro DRUGeff 
testing of all compounds show interaction with the target treatment, until a 
small portion of dose gets to select according to biophase levels. Concentration of 
treatment dose maximization per unit of biophase acts as a key objective for lead 
optimization. The drugs qualifying this test enter into the clinical phase [77].
7.4 Clinical phase of drug discovery
The final step of drug discovery and development is referred to as the clinical 
trial. At this stage, the data regarding safety and efficacy of the new drug must be 
proven by application to humans directly in different phases. After the successful 
trials, research data is sent to the FDA for approval for commercial manufacturing 
and marketing (Figure 6 ) [78].
7.4.1 Clinical phase I
The first phase of clinical trial normally takes several weeks to some months. 
At this stage application of optimized drug is tested on a small group of volunteers. 
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They may or may not get paid for their participation in drug trial studies. This mini 
trial is useful in determining the absorption and side effect of drug in relation to its 
dose concentration [17].
7.4.2 Clinical phase II
The second phase of clinical trial may last up to 2 years. It is a totally randomized 
study which involves the application of drug on a relatively large group of patients. 
This trial study is divided into two groups of patients, one receiving experimental 
drug and the other receiving placebo. Sometimes it may be named as a blind 
application trial. This type of random application of drug allows investigators and 
pharmaceutics to prove the success and safety of drug to the FDA with comparative 
information [79].
7.4.3 Clinical phase III
It is a large-scale testing of drugs on hundreds of patients. This third stage 
testing provides with a more thorough understanding and effectiveness of useful 
drugs to the FDA and pharmaceutical companies. The pharmaceutical company 
can request for the approval for commercial synthesis of drug after phase III is 
completed [80].
7.4.4 Clinical phase IV
After the approval of a drug for commercial consumption, clinical phase IV 
trials are used as post marketing surveillance trials. This trial system is based upon 
the various objectives at commercial levels, i.e., the comparison of newly approved 
and already-available drugs in market, to evaluate the chronic effects on patients’ 
quality of life and to estimate the economical comparison of newly approved and 
already-present drugs as well as the traditional system of medication [81].
Figure 6. 
The journey of potential leads from preclinical to clinical trials.
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8. Conclusion and future perspectives
Chemical biology is an emerging field of science which particularly focuses on 
the research in biological systems by employing the chemicals and related chemoin-
formatic tools. This field of study is working well in combination with medicinal 
and combinatorial chemistry to seek the cure of incurable and life-threatening 
human pathologies. This chapter illustrated the significant techniques and chemical 
setups which can be employed to testify the chemical as well as biological aspects 
of natural and synthetic compounds before introducing them as therapeutic drugs 
in the field of medicine. There is an ultimate need of the hour to seek for the newer 
and better drugs which are safer, cheaper, and more effective than the already 
existing therapeutics. This field of study is flourishing at a very fast pace, and it is 
anticipated that it will provide better treatment options and strategies in future for 
the medical practitioners to use the best among the rest drugs discovered.
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